Rani Therapeutics Highlighted RT-111 Development Program for Multiple Indications
- The company reported the preclinical development of RT-111, a RaniPill GO capsule containing a biosimilar of Stelara (ustekinumab)
- The results from part 1 of the P-I study for RT-102 meeting all of the EPs & were well-tolerated. RT-102 orally delivered 20 & 80µg of PTH with 300-400% greater bioavailability over Forteo (20µg, SC). The repeat-dose results from Part 2 of the P-I study for RT-102 for the treatment of osteoporosis are expected in Q4’22
- The company plans to initiate in vivo studies with a fully-autonomous RaniPill HC in Q4’22 to deliver payloads of ~20mg with high bioavailability. The P-II study of RT-102 & P-I study with three pipeline molecules is expected to be initiated in 2023
Ref: Globenewswire | Image: Rani Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.